Refine by
Expression System For Protein Expression Articles & Analysis
76 news found
Creative BioMart, a biotechnology company focused on protein-related research solutions, has recently upgraded its epitope mapping service to better support researchers in therapeutic antibody development, vaccine design, and immunogenicity studies. The updated platform integrates multiple experimental approaches with customizable strategies, enabling more accurate identification of antibody ...
Creative BioMart, a leading global supplier of recombinant proteins and related research products, is excited to announce the launch of Its Monthly Special Release, a new program offering exclusive discounts of up to 50% off on a curated selection of products each month. With over 100,000 recombinant protein products in stock and a commitment to continuously launching new offerings based on ...
Compared to costly animal models, assays using 3D-cultured cells are rapid, cost-effective, versatile, and easily reproducible. To date, 3D cell culture systems, including scaffold-based and scaffold-free, have been widely applied in differentiation studies, drug discovery, cancer research, gene and protein expression studies, and cellular ...
ExcellGene SA, a leading Swiss biotech service provider specializing in mammalian cell line development for more than two decades, proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization (CDMO) based in the USA. As CHO (Chinese Hamster Ovary) and HEK (Human Embryonic Kidney) cells are the most well-suited mammalian ...
Amerigo Scientific, a distributor focused on providing critical products and services to biomedical and life science communities, is proud to showcase its featured offering in cell-free protein expression supplies - the pEU vector set. This innovative vector set allows for efficient and reliable protein expression in a cell-free ...
Creative Enzymes, a global leader in enzyme production, is thrilled to announce the latest addition to their hydrolase product line, the Recombinant S-Adenosyl-L-Homocysteine Hydrolase (SAHH). This announcement underscores its unwavering commitment to enzyme innovation and proven track to offering scientifically advanced products. SAHH, a crucial enzyme involved in the biological methylation ...
BOC Sciences expressed its congratulations to Katalin Karikó and Drew Weissman for being recipients of the 2023 Nobel Prize in Physiology or Medicine. The Royal Swedish Academy of Sciences recognized Dr. Karikó and Dr. Weissman's remarkable contributions to science, specifically acknowledging their game-changing discoveries in nucleoside base modifications. BOC Sciences, which ...
Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS (“bYoRNA”) today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA (“mRNA”). Dyadic is a global biotechnology company focused on building innovative ...
For the expression of proteins in insect cells, the Baculovirus Expression Vector System (BEVS) is a potent tool. ...
CD BioGlyco, a biotechnology company that provides multi-omics analysis of cancer cell glycolysis including genomics, proteomics, metabolomics and metabolic fluxomics, now offers analysis of glycolytic enzymes in cancer cells, enabling thorough understanding of cancer cell glycolysis pathways. The capacity of cancer cells for aerobic glycolysis is 20–30 times greater than that of normal ...
Of course, mRNA transfection is limited to instantaneous expressions. Unlike DNA and viral vectors, mRNA will not be inserted into the host genomes that modify genetic information, and proteins encoded by mRNA fragments will only be expressed instantaneously and then degraded rapidly, minimizing the risk of gene integration and being highly safe. ...
LenioBio develops efficient and sustainable technologies for protein expression. Company with a clear goal: To simplify protein production and accelerate the delivery of drugs to patients. Revolutionizing Biopharma manufacturing LenioBio develops efficient and sustainable technologies for protein expression. Company with a clear goal: To simplify protein production and accelerate the delivery of ...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that topline data from the ongoing Phase 3 MANIFEST-2 study – a global, randomized, double-blind clinical trial exploring pelabresib, an investigational BET inhibitor, in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis – are expected to be available in early 2024. The company previously ...
Data from the MANIFEST trial show durable improvements in both spleen volume and symptom score beyond 24 weeks with pelabresib in combination with ruxolitinib for JAK inhibitor-naïve patients An exploratory analysis of biomarkers from the MANIFEST trial indicates the potential for disease modification MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced results from analyses of the ...
Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced the publication of data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria. The research, conducted in collaboration with the University of Washington, was published in the peer-reviewed journal, Nature Partner ...
(NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announces preliminary unaudited financial results for the fiscal year ended June 30, 2022, and provides a corporate update. ...
The acquired assets include a patented system that uses artificial intelligencey (Al) to design 3D models of epitopes - which are the part of an antigen that is recognized by the immune system -to facilitate the creation of better antibody drug candidates (ADCs). The other assets are two previously licensed candidates and three new immune-oncology therapeutic ...
The acquired assets include: AI Drug Discovery Platform: A patented system that uses artificial intelligence (“AI”) to design 3D models of epitopes to facilitate the creation of better antibody drug candidates. ...
In order to express immunogenic glycoproteins, CD BioGlyco has developed glyco-engineered yeast systems, plant systems, insect cell systems, mammalian cell systems, and viral vector systems. Related studies on the structural resemblances between them and the natural antigen and how they affect ...
August 29, 2022, Baltimore, MD and Indianapolis, IN – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, today announced the launch of a partnership with Helix BioStructures, a pharmaceutical-biotech contract research organization that provides high-quality, integrated drug discovery services to the pharmaceutical community in the ...